CLINICAL_TRIALS
trial_result
· 2017-10-31
Clinical Trial Update: Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma [Phase 2]
Summary
Phase 2 study evaluating inotuzumab ozogamicin (CMC-544) in indolent non-Hodgkin lymphoma has completed and results were posted in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2017-10-31